I have set a new intention to collate my clinical thoughts, initially I thought once a week but knowing my time limitation it might be more like once a month!
I will share themes I have noticed within my practice and interesting research papers that I have found as a result of seeing certain presenting conditions.
I hope you find it as interesting and useful as I do!
I often find myself supporting people on their cancer journey.
Herbs and nutritional medicine in the form of nutritional supplements as well as food plans can really play a positive role regardless of which stage of their journey a person arrives to work with me, pre or post or even during conventional medical treatment.
This week I wanted to check the dose of Frankincense resin when used as a supportive herb after Steretactic treatment ( Radiotherapy) in the case of Brain Tumours.
I remember some years ago during a CPD Seminar an MRI was presented as before and after integrative treatment and the tumour was significantly reduced.
One of the key herbs discussed during the seminar was Frankincense and this sacred herb came to mind during a conversation I had twice this week.
Frankincense or Boswellia serrata contains Boswellic acids which are well known for their anti-inflammatory effects, they are largely resinous compounds with a percentage of volatile oil and a small amount of mucilage.
Often Medical Herbalists will use this herb to help with Osteoarthritis as well as inflammatory bowel disease such as Ulcerative Colitis or Crohns.
I often use the Essential Oil topically in chest balms for Asthma.
The research on the use for malignant brain tumours as an adjunct pharmacological agent is very interesting and encouraging.
I found this study published in Oncology Letters very promising and informative and fairly recent too – 2016.
It is certainly not a new concept as Boswellia has long been considered useful in Integrative Medicine for both malignant gliomas and brain metastasis over the last decade, mostly in central European countries.
The anti-inflammatory action is thought to be beneficial where there is oedema ( swelling) which is a common problem in growing brain tumours, and often controlled with steroid medication which comes with it’s own issues of course.
Some Cell Culture studies also suggest that there are intrinsic anti tumour cell properties and one invivo ( rat study) showing cell apoptosis ( cell death) is quite encouraging:
Boswellic acids inhibit glioma growth: a new treatment option?
The study of 2016 also finds anti inflammatory and cytotoxic properties and is quite positive in encouraging the use alongside conventional treatment but of course invivo ( in the living organism) studies are needed to corroborate.